EDX Insider Trading

EDX Medical Group plc (“EDX”) creates and supplies innovative medical diagnostic tests to improve the early detection and characterisation of major diseases such as cancer and infectious diseases. The Company operates from a molecular biology and diagnostics laboratory in Cambridge, UK, providing testing services accredited to ISO 15189 (2022) by the United Kingdom Accreditation Service (UKAS), Products include include EDX’s own tests and laboratory services as well as other best-in-class tests, ensuring diverse revenue streams. The company has already brought to market advanced bowel and testicular cancer testing services offering exceptionally high levels of accuracy and sensitivity, in addition to a new test for pneumonia for use in hospital intensive care units and a test for toxicity in chemotherapy treatment These are sold to patients, GPs, healthcare providers, private hospitals and insurers, in addition to the NHS. EDX was founded by Professor Sir Chris Evans, OBE, one of Europe’s most experienced life sciences leaders who has built numerous companies, more than 20 of which have gone on to be listed on stock exchanges internationally and generated multi-billion pound returns to investors.